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Summary 
Individuals with X-linked hyper-IgM syndrome fail to express functional CD40 ligand (CD40L) 
and, as a consequence, are incapable of mounting protective antibody responses to opportunistic 
bacterial infections. To address the role of CD40L in humoral immunity, we created, through 
homologous recombination, mice deficient in CD40L expression. These mice exhibited no gross 
developmental deficiencies or health abnormalities and contained normal percentages of B and 
T cell subpopulations.  CD40L-deficient mice did display selective deficiencies in humoral immunity; 
basal serum isotype levels were significantly lower than observed in normal mice, and IgE was 
undetectable. Furthermore, the CD40L-deficient mice failed to mount secondary antigen-specific 
responses to immunization with a thymus-dependent antigen, trinitrophenol-conjugated keyhole 
limpet hemocyanin (TNP-KLH). By contrast, the CD40L-deficient mice produced antigen-specific 
antibody of all isotypes except IgE in response to the thymus-independent antigen, DNP-Ficoll. 
These results underscore the requirement of CD40L for T  cell-dependent antibody responses. 
Moreover, Ig class switching to isotypes other than IgE can occur in vivo in the absence of CD40L, 
supporting the notion that alternative B cell signaling pathways regulate responses to thymus- 
independent antigens. 
ntigen (Ag)-specific activation of B cells occurs in two 
distinct steps.  In the first, Ag binds to membrane Ig 
on the B cell surface, is degraded and processed, and is then 
presented on the cell surface in association with MHC class 
II molecules (1, 2). The second step involves the recognition 
of the Ag-MHC class II complex by T  cells that become 
activated and deliver a stimulatory signal back to the B cells 
(3, 4). Whereas Ag recognition by T cells is MHC-restricted, 
the subsequent signal delivered by the helper T  cell to the 
Ag-presenting B cell is both Ag-independent and genetically 
unrestricted (5-8). Recently, the ligand for CD40 (CD40L) t 
has been identified as a major component of contact-dependent 
T  cell-mediated B cell activation (9-11). 
CD40L is a 33-kD glycoprotein that is transiently expressed 
on the surface of activated T  cells,  predominantly of the 
CD4 + phenotype (10, 12, 13). CD40L provides a mitogenic 
signal to B cells, the potency of which is enhanced by soluble 
cytokines, notably IL-4 and IL-5 in the mouse (14) and IL-4 
and IL-10 in the human (15,  16). These same cytokines to- 
1 Abbreviations used in this paper: BGG, bovine 3' globulin; CD40L, CD40 
ligand; ES,  embryonic stem; HIGM, hyper-IgM syndrome; HKP, 
horseradish  peroxidase;  KO, knockout;  TD, thymus-dependent;  TI, thymus- 
independent; TNP, trinitrophenol. 
gether with CD40L also provide costimulatory signals that 
induce secretion of polyclonal Ig of multiple isotypes (14-17). 
The process orB cell affinity maturation and isotype switching 
after antigenic challenge requires CD40L.  Defects in  the 
CD40L gene result in X-linked hyper-IgM syndrome (HIGM), 
a condition characterized by elevated serum concentrations 
of IgM with a virtual absence of other Ig isotypes, an in- 
creased susceptibility to opportunistic bacterial infections, and 
an absence of germinal centers in secondary lymphoid tissue. 
Experimental evidence for the role of CD40L in the genera- 
tion of Ag-specific B cell responses came from studies that 
demonstrated that in vivo administration of a neutralizing 
antibody specific for murine CD40L inhibited both the pri- 
mary and secondary Ag-specific humoral response to thymus- 
dependent (TD) antigens (18). In addition to its activities 
on B cells, CD40L has stimulatory effects on monocytes, in- 
ducing cytokine secretion and tumoricidat activity (19), and 
on T  cells where it costimulates proliferation and cytokine 
secretion and  induces the  generation of cytolytic T  cells 
(20-22). 
To better understand the requirements for CD40L func- 
tion in an in vivo context, we have generated mice containing 
a disrupted CD40L gene. We demonstrate in this report that 
these CD40L "knockout mice" (CD40LKO)  are unable to 
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to develop germinal centers in secondary lymphoid tissue after 
antigenic challenge. These mice can, however, respond to a 
thymus-independent (TI) Ag as demonstrated by their ability 
to generate Ag-specific Ig of all isotypes except IgE. The results 
suggest that  the CD40LKO  mouse will be a useful model 
for further studies on the role of CD40L and other cell sur- 
face molecules in various aspects  of the immune response. 
Materials  and Methods 
Animals.  Experiments were performed with C57BL/6 (Charles 
River Laboratories, Wilmington, MA) or Swiss Webster (Taconic 
Farms Inc., Germantown, NY) mice. Animals were maintained 
under specific pathogen-free conditions. 
Reagents.  The following reagents were used for in vitro B cell 
assays: recombinant murine IL-4 (Immunex Corp.) and IL-5 (R&D 
Systems Inc., Minneapolis, MN); Salmonella typhimurium  LPS (Difco 
Laboratories,  Detroit, MI); affinity-purified  goat anti-mouse IgM 
(Southern Biotechnology Associates,  Birmingham, AL); recom- 
binant murine soluble  CD40L (Immunex). CD40L was purified 
from conditioned medium of Chinese hamster ovary (CHO) cells 
stably expressing a cDNA plasmid encoding a fusion protein con- 
sisting of CD40L (extracellular region) and a modified leucine zipper 
motif, resulting in secretion of a soluble, trimeric form of CD40L 
(23). The following ELISA reagents were employed: unconjugated 
and horseradish peroxidase (HRP)-conjugated affinity-purified goat 
anti-mouse IgM, IgA, IgG1, IgG2b, and IgG3 (Southern Biotech- 
nology Associates);  and unconjugated and biotinylated rat anti- 
mouse IgE (Bioproducts for Science, Indianapolis,  IN). 
Conjugated antibody reagents were used to detect surface ex- 
pression of hematopoietic cell markers.  Surface IgD + and surface 
IgM* B cells were detected using biotin-labeled mouse anti-IgD  b- 
clone 217-170 (PharMingen,  San Diego, CA) and goat (F(ab')2) 
anti-mouse-IgM-FITC conjugate (Tago, Inc., Burlingame, CA), 
respectively. B cells were also monitored using CD45R-FITC (Phar- 
Mingen). T cell subsets were analyzed using CD3-FITC (22), CD4- 
FITC and CD8-FITC (Caltag Laboratories,  San Francisco,  CA). 
CDllb-biotin  (PharMingen)  was  used  to  detect  macrophages. 
Mouse IgG1-FITC and IgGl-PE-conjugated control mAb were ob- 
tained from Becton Dickinson & Co.  (Mountain View,  CA). 
Gene Targeting Vector  Construction.  All DNA manipulations were 
performed using standard methodology (24). To facilitate construc- 
tion of a targeting vector, a murine (129/SV stain) X genomic li- 
brary (Stratagene, La Jolla, CA) was screened using a radiolabeled 
CD40L cDNA probe based upon the 800 bp SalI-PstI fragment 
of murine CD40L (12). Two clones were subsequently restriction 
mapped  and  used  to  construct  the  targeting  vector,  pGEMll 
(Promega Corp., Madison,  WI) was  used as the cloning vector 
throughout, pHRV-mCD40L was constructed by inserting a 1.3-kb 
XbaI-SpeI genomic fragment (located ,-800 bp downstream of exon 
2) 5' of the neomycin phosphotransferase gene driven by the mu- 
rine PGK-1 promoter (PGK/Neo) (25).  A  12.2-kb  HindlII-SalI 
genomic fragment (containing exon 5) followed by the HSV-TK 
gene (26) was inserted immediately 3' of PGK/Neo. The replace- 
ment vector was designed to delete exons 3 and 4 after homolo- 
gous recombination. 
Electroporation,  Selection, and Analysis of  Embryonic  Stem (ES) Cells. 
After llnearization with NotI, pHRV-mCD40L was electroporated 
into the ES cell line D3 (27) at 200 V and 960 gF. Cells were cul- 
tured on a feeder layer of 3,-irradiated, neomycin-resistant STO cells 
expressing LIF and were selected in 175 #g/ml G418 (GIBCO BRL, 
Gaithersburg, MD) plus 2 mM gancyclovir (Syntex, Palo Alto, CA) 
for '~10 d. After selection,  plates were washed once with PBS and 
flooded with trypsin. After 2 min, the trypsin was removed and 
replaced with serum-containing medium. Individual colonies were 
isolated in 100 gl media and dispersed by repeated pipetting in a 
96-well plate. Clones were then plated singly and analyzed via PCR 
in pools of five clones. 
Targeted ES clones were identified by PCR amplification  using 
an  antisense  primer  specific  for the  PGK-1  promoter  (PI:  5'- 
CTTGTGTAGCGCCAAGTG-3') in conjunction with a CD40L 
intronic primer that lies immediately upstream of the 5' terminus 
of pHRV-mCD40L  (P2:  5'-GTATGTGGCTGAACACCTG-Y). 
PCR analysis was performed in 100 gl reaction volumes in 50 mM 
KC1, 1.5  mM MgClz,  10 mM  Tris-C1, pH  8.4,  200 #M  each 
dNTP, 25 pmol each primer, and 2.5 U  Taq polymerase (Perkin- 
Elmer Cetus, Norwalk, CT). 30 cycles were performed at 94~ 
for  1  min,  52~  for  1  min,  and  72~  for  1.5  min.  After 
amplification, 20 gl of each reaction were separated by electropho- 
resis on 1% agarose gels, and product was visually observed after 
staining with ethidium bromide. The presence of a 1.6-kb product 
indicated homologous recombination. 
Homologous recombination in PCR-positive clones  was con- 
firmed by genomic Southern blot analysis. High molecular weight 
DNA (15 gg) was digested with PstI, electrophoresed through 1% 
agarose, blotted to nitrocellulose, and probed with a radiolabeled 
400-bp XbaI-PstI genomic fragment located upstream of the 5' 
terminus of pHRV-mCD40L. This probe hybridized to a 9.0-kb 
PstI fragment in wild-type genomes, while gene targeting intro- 
duced a new PstI  site 2.2  kb downstream of the 5' PstI  site. 
Generation of CD4OL-deficient Mice.  Cells from one clone, no. 
9-72, were injected into day 3.5 blastocysts isolated from C57BL/6 
mice and carried to term in pseudopregnant Swiss Webster females. 
Resultant male chimeras were subsequently mated with wild-type 
C57BL/6 females to derive females heterozygous for the targeted 
mutation. [129/SV  x  C57BL/6] F1 heterozygous females (+/-) 
were then crossed with C57BL/6 males to derive the hemizygous 
(-/0) and wild-type (+/0) male animals analyzed in the present 
study. 
Progeny from the above matings were genotyped via four-primer 
PCR of ear biopsy DNA extracts.  Two primers specific for the 
region deleted in targeted mutants  (P3:  5'-CCCAAGTGTATG- 
AGCATGTGTGT-Y and P4: 5'-GTTCCTCCACCTAGTCATTCA- 
TC-Y) amplify a 250 bp product from the wild-type allele only. 
These were used  in conjunction with  two primers  specific for 
PGK/Neo (PS: 5'-GCCCTGAATGAACTGCAGGACG-3' and P6: 
5'-CACGGGTAGCCAACGCTATGTC-Y) that amplify a 500-bp 
band in the mutant allele only. 35 cycles were performed at 94~ 
for i rain, 60~  for 30 s, and 72~  for 30 s. Representative progeny 
were also analyzed by genomic Southern blotting as described above. 
Histochemical  Analysis.  Spleen or lymph node (LN) specimens 
were coded and examined in a blinded fashion.  For histological 
studies, tissue samples of the spleen and LNs were fixed in Meth- 
carnoy's fixative (28) for 1 h at room temperature. Further tissue 
processing was performed on a tissue processor (V.I.P., Miles Labora- 
tories, Inc., Naperville, IL) as follows:  dehydration in  100%  al- 
cohol, clearing in Shandon's Xylene substitute (Shandon, Inc., Pitts- 
burgh, PA), and infiltration in Tissue Prep paraffin. Specimens were 
then embedded in Tissue Prep 2 paraffin (Fisher Scientific, Fairlawn, 
NJ), sectioned at 3 #M and stained with hematoxylin and eosin. 
Flow Cytometric Analysis of Cell Surface Ag Expression.  Lym- 
phoid organs were harvested aseptically and cell suspensions  pre- 
pared from LN and spleen and resuspended in PBS containing 1% 
FCS, 10% normal goat serum and 0.1% NaN3 before cytofluoro- 
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and IL-4R.Fc)  and one- or two-color flow cytometric analysis  was 
performed as described (12). 
Immunization  Protocols 
TD Ag.  Trinitrophenol-conjugated  keyhole  limpet hemocyanin 
(TNP-KLH) was precipitated with alum under pyrogen-free con- 
ditions. On day 0 of the immunization protocol, mice were in- 
jected intraperitoneally with 1/~g of TNP-KLH in a volume of 
200/xl. Identical secondary immunizations were administered on 
day 21. Mice were bled on day 0 and on day 26 and serum was 
prepared for ELISA analysis. 
7"1-2 Ag.  On day 0 of the immunization protocol, mice  were 
injected intraperitoneally  with 10/xg (100 #1) of  DNP-Ficoll, gener- 
ously provided  by Dr. Bondada Subbarao (University of Kentucky, 
Lexington, KY). On day 10, mice were bled and serum was pre- 
pared for ELISA analysis. 
Determination of Serum Polyclonal and Anti-TNP Ig Levels.  Serum 
polyclonal IgA, IgE, IgG1, IgG2b, IgG3, and IgM levels were de- 
termined by an isotype-specific ELISA technique as previously 
described (29). Briefly, individual wells of 96-well plates (Flow 
Laboratories Inc.,  McLean, VA)  were coated with anti-mouse 
isotype-specific antibody and blocked with 5% nonfat dry milk 
in PBS. Serially diluted serum samples were added, followed by 
the appropriate HRP-conjugated second-step antibody. For the IgE 
isotype specific  assay,  biotinylated rat anti-mouse IgE was used as 
second antibody reagent and HRP-conjugated streptavidin  (Zymed 
Laboratories, Inc., S. San Francisco,  CA) was used in the following 
step. All assays  were developed  using the TMB Microwell peroxi- 
dase substrate system (Kierkegaard and Perry Laboratories, Inc., 
Gaithersburg, MD). Ig concentrations in serum test samples were 
determined by comparing test sample dilution series values with 
isotype control standard  curves  using the DeltaSoft 2.1 ELISA  anal- 
ysis program (Biometallics, Inc., Princeton, NJ). Where indicated 
in Results, Student's t test (for two samples assuming unequal vari- 
ance) was used to generate p values. 
Anti-TNP Ig isotype levels were determined by a modified sand- 
wich ELISA method (30). Plates were coated with goat anti-Ig 
isotype, blocked with nonfat dry milk, and incubated with serially 
diluted test serum samples. Biotinylated TNP-bovine 3' globulin 
(TNP-BGG) was used as a third step followed  by HRP-conjugated 
streptavidin. Wells were developed  with peroxidase substrate and 
analyzed as described above. Multiple point analysis  was performed 
on each set of isotype titrations using the BIOASSAY program, 
selecting a maximum value for each isotype and determining for 
each sample the dilution giving half-maximal  OD value, thus gener- 
ating arbitrary U/ml values as previously described (30). 
Splenic B Cell Culture.  B lymphocytes  were purified  from spleens 
as previously described (31) by a combination of T cell depletion 
with antibody plus C', adherent cell depletion over Sephadex G10 
columns, and positive selection  on anti-IgM coated  pans. The resul- 
tant preparations were >99% pure B cells as determined by flow 
cytometric analysis for surface IgM expression. B cells were cul- 
tured in RPMI 1640 supplemented  with 5% FCS (JRH Biosciences, 
Lenexa, KS), sodium pyruvate (1 raM), nonessential amino acids 
(0.1 mM), penicillin (100 U/ml), streptomycin (100/xg/ml), r-glu- 
tamine (2 mM), and 2-mercaptoethanol (50/~M). For proliferation 
assays, B cells (10Vwell; 200 #1) were cultured in 96-well flat- 
bottom tissue culture plates (Costar Corp., Cambridge, MA) with 
or without 10 ng/ml each of II.-4 and 11.-5 either alone or in the 
presence of LPS, goat anti-mouse IgM, or purified recombinant 
soluble CD40L. Cultures were pulsed for the last 16 h of a 72-h 
culture period with 2/~Ci/well of [3H]thymidine (25 Ci/mmol; 
Amersham Corp., Arlington Heights, IL) for 16 h. Cells were then 
harvested onto glass fiber filters, and incorporation of radioactivity 
was measured by tritium sensitive avalanche  gas ionization detec- 
tion on a Matrix 96 Direct Beta Counter (Packard Instruments, 
Meriden, CT). 
For polyclonal Ig secretion, B cells (5  x  105 cells/well) were 
grown in 96-well flat-bottomed plates for 6 d either alone or in 
the presence of IL-4 plus IL-5 (each at 10 ng/ml) plus recombinant 
soluble CD40L or LPS. Cells were then pelleted by centrifugation 
at  750  g,  and  culture  supernatant  fluids were harvested for 
quantification of Ig levels by isotype-specific  sandwich ELISA as 
described above. 
Results 
Generation of CD#OL-deficient Mice.  To generate a null mu- 
tation in the murine CD40L gene (Fig.  1 A),  a targeting 
vector employing a standard positive-negative selection (26) 
was constructed,  pHRV-mCD40L (Fig. 1 B) contains 13.5 kb 
of CD40L genomic sequences in which the positive selection 
marker, PGK/Neo (25) is flanked by a 12.2-kb HindIII-SalI 
genomic fragment (containing exon 5) on the Y  side, and 
a 1.3-kb XbaI-SpeI genomic fragment (located 800 bp 3' of 
exon 2) on the 5' side. The HSV TK gene (26) was added 
3' of the 12.2-kb stretch of homology to select against random 
integration events. The vector was designed to delete exons 
3 and 4 of CD40L after homologous recombination at the 
endogenous gene (Fig.  1 C). 
ES ceils of the 129/SV-derived line D3 (27) were electropo- 
rated with NotI-linearized vector and selected in the pres- 
ence of G418 and gancyclovir.  80 colonies surviving double 
selection  were screened for targeting events by PCR using 
a primer specific for the endogenous gene (Fig.  1 A) and an 
antisense primer specific for PGK/Neo (Fig. 1 B). The pres- 
ence of a 1.6-kb product was indicative of homologous recom- 
bination and was observed after amplification of two clones. 
Thus the frequency of homologous recombination was 1 in 
40 doubly resistant clones. Gene targeting was confirmed by 
genomic Southern blot analysis. 
One targeted ES clone, no. 9-72, was injected into C57BL/6 
blastocysts which were then transferred into pseudopregnant 
recipient females (Swiss Webster) to generate chimeras. Germ- 
line transmission and subsequent segregation of the mutant 
allde was monitored by PCR amplification using four primers 
simultaneously (Fig.  1 D). Two primers (P3 and P4) define 
a 250-bp product within the region deleted by gene targeting 
and amplify exclusively the wild-type allele. The other two 
primers (P5 and P6) are specific for PGK/Neo and amplify 
only a 500-bp  product from the mutant allele. The geno- 
types of representative  animals were  further  analyzed by 
genomic Southern blotting (Fig. 1 E). The radiolabeled probe 
hybridized to a 9.0-kb PstI-generated band in wild-type ge- 
nomes. Gene targeting, however, introduced a new PstI site 
downstream of the 5' PstI site, resulting in a 2.2-kb band 
(Fig.  1 E).  [129/SV  x  C57BL/6]F1 female heterozygotes 
(+/-)  were crossed  to wild-type C57BL/6 males to yield 
the hemizygous (-/0) and wild-type (+/0) male animals ana- 
lyzed in the present work. Experimental animals were all 6-8- 
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Figure  1.  Targeted mutation of the X-linked murine CD40L gene. (.4) 
Schematic diagram of the wild-type allele. Exons are represented as thick, 
black boxes.  ($) SpeI; (X)  XbaI; (P) PstI; (N) Notl. P3 and P4 are PCR 
primers specific to the region deleted in the targeted allele. (B) Gene tar- 
geting vector, pHRV-mCD40L. P1 represents the PCR primer used with 
P2 (endogenous gene primer) to detect homologous recombination events. 
(C) Structure of the mutant CD40L allele. P5 and P6 are neomycin phos- 
photransferase gene PCR primers unique to the mutant allele. The 400-bp 
XbaI-PstI  fragment  located just downstream  of exon 2 was used as the 
probe in (D).  (D) Genotype analysis of ear biopsy DNA. Heterozygous 
females were crossed with wild-type male C57BL/6 mice. DNA extracted 
from ear biopsy samples were coamplified with primers P3,  P4, PS, and 
P6. Primers P5 and P6 amplify a 500-bp product from the mutant allele 
only, and P3 and P4 define a 250-bp amplification product specific to the 
wk of age. All male hemizygotes  and female homozygotes 
were viable and fertile with segregation of the mutant allele 
following a typical, Mendelian pattern.  Sex ratios among 
offspring and the gross external phenotype  of these animals 
were  also normal. 
Cell-Surface  Ag Expression  and CD40L Expression in CD40- 
LKO and ControlMice.  LN T cells were obtained from both 
CD40LKO  and littermate control  mice and then activated 
with  immobilized  anti-TCR-od3  mAb  under conditions 
known to induce CD40L expression and maintain CD4 ex- 
pression in  normal animals. CD40L  expression was deter- 
mined by double  staining of the activated LN T cells with 
CD4-FITC and with huCD40.Fc-biotin  plus PE-conjugated 
streptavidin, followed by two-color flow cytometric analysis. 
Results indicated that 26.3%  of activated CD4 § LN T cells 
from littermate controls displayed binding of CD40.Fc rela- 
tive to binding  of a control protein (IL-4R.Fc)  (Fig. 2, A 
and B). This is consistent with previous reports demonstrating 
that a subset of CD4 + T  cells express CD40L in response 
to anti-TCR stimulation (13, 15, 32).  By contrast, the acti- 
vated CD4 + LN  T  cells  from  CD40LKO  mice  failed to 
bind detectable levels of CD40.Fc, indicating a total absence 
of functional CD40L expression on the cell surface (Fig. 2, 
C and D). No detectable ligand expression was observed on 
either control- or CD40LKO-derived CD4 + T cells cultured 
in medium  alone (data not shown). 
Flow cytometric analysis was performed on cells from naive 
CD40LKO and naive control mice in order to compare leu- 
kocyte  subpopulations.  Relative  to  controls,  CD40LKO- 
derived spleens and LNs contained similar percentages of B 
cells  (as measured by surface IgD,  surface IgM,  and B220 
wild-type allele. (E) Southern blot analysis of the mutated CD40L gene. 
Genomic DNA (15/zg) was digested with PstI, electrophoresed through 
agarose, blotted  to nitrocellulose,  and hybridized to the probe indicated 
above. Positions of hybridizing  bands (2.2 kb for the mutant allele; '~9.0 
kb for the wild-type allele) are indicated. 
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Figure 2.  CD40L  expression  is undetectable  on activated  CD4 + LN 
T  cells obtained from CD40LKO mice. LN T  cells obtained from 
CD40LKO and control mice were activated for 18 h with immobilized 
anti-TCR mAb and double  stained with either  hulL-4R.Fc-biotin  (.4 and 
C) or huCD40.Fc-biotin (B and/9) and CD4-FITC (A-D) as described 
in Materials and Methods. The results are representative  of the staining 
on three CD40LKO mice and two control mice. 
expression) and T  cell subsets (as measured by CD3, CD4, 
and CD8 expression) (Table 1). These tissues also contained 
normal  ratios  of CD4 +  and  CD8 +  populations.  Results 
from four additional experiments were consistent with these 
findings. Thus, there did not appear to be any gross pheno- 
typic  differences  in  lymphocyte  subpopulations  between 
CD40LKO and normal mice. However, there were differ- 
Table  1.  Cell Surface Marker Analysis  of Spleen  and LN  Cells 
ences in numbers of cells recovered from CD40LKO LNs 
when compared with control littermate LNs. The results in 
Table 2 show that total LN cellularity was approximately two- 
to threefold lower in CD40LKO mice. 
Humoral Immune Responsiveness.  Although most HIGM 
patients display elevated levels of circulating IgM compared 
with normal subjects, they are severely deficient in other serum 
isotypes. To determine whether CD40LKO mice exhibit the 
same phenotype, serum was collected from two groups of 
mice (control and CD40LKO) at 30,  44,  58,  and 72 d  of 
age, and isotype concentrations were determined by ELISA. 
Results in Fig.  3 demonstrate that IgM levels were essen- 
tially identical between the two groups at all ages. IgG3 levels 
were similar between the two groups although older mice 
displayed some differences (2 <.038 between CD40LKO and 
control mice on day 72).  Differences in serum levels were 
more pronounced for the other isotypes, with considerably 
lower IgA (2 <.004), IgG1 (2 <.026), and IgG2b (2 <.028) 
in CD40LKO mice on day 72.  In this and several other ex- 
periments, the CD40LKO mice consistently demonstrated 
a complete absence of IgE (detection limit of 0.02 ng/ml); 
by contrast IgE is always detectable in serum from control 
mice, although as demonstrated in this experiment the levels 
may vary considerably between individual mice. 
The ability orB cells to secrete antibody and undergo class 
switching in response to certain antigens, particularly soluble 
protein antigens, requires T  cell help that is at least in part 
mediated through CD40L-CD40 interactions (18,  33).  To 
test the hypothesis that CD40LKO mice are incapable of re- 
sponding to a typical "T-dependent" Ag, CD40LKO, and 
control mice received primary (day 0) and secondary (day 21) 
injections of TNP-KLH in alum,  then were bled 5 d later 
to measure anti-TNP antibody levels by ELISA. Control mice 
produced significant levels of anti-TNP IgA, IgE, IgG1, IgG2a, 
IgG2b,  IgG3  (Table  3),  and  IgM  (Fig.  4);  in  contrast, 
Isolated From  Control or CD4OLKO  Mice 
B cell subset  T  cell subset  Mac subset 
IgD  b  +  IgM +  B220 +  CD3 +  CD4 +  CD8 +  Mac-  1 
Spleen 
Control no.  1  33  70  62  27  17  12  8 
Control no.  2  55  63  55  36  24  12  10 
CD40LKO no.  1  31  67  58  31  19  13  7 
CD40LKO no. 2  40  74  65  22  14  8  10 
Lymph node 
Control no.  1  15  34  35  67  43  24  4 
Control no.  2  30  35  31  65  45  21  3 
CD40LKO no.  1  15  35  33  64  46  18  3 
CD40LKO no. 2  19  44  37  56  36  21  2 
Numbers represent  percent positive  cells for the surface  protein being examined. Gating parameters were dependent on autofluorescence  and isotype 
control antibody binding. 
1893  P._enshaw  et al. Table  2.  Lymph Node  Cellularity in Control and CD4OLKO Mice 
Total Cells  x  10 -6*  xt 
Expt.  1 
(popliteat,  inguinal,  brachial) 
Expt.  2 
(axillary, brachial,  cervical, inguinal,  periaortic) 
Expt.  3 
(axillary, brachial,  cervical, inguinal,  periaoritc) 
Control no.  1  1.8  2.1 
Control no.  2  2.5 
CD40LKO  no.  1  0.9  0.9 
CD40LKO  no.  2  1.0 
Control  no.  1  23.2  26.2 
Control  no.  2  29.2 
CD40LKO  no.  1  7.0  7.3 
CD40LKO  no.  2  7.5 
Control no.  1  31.9 
Control no.  2  24.4  24.8 
Control no.  3  18.0 
CD40LKO  no.  1  10.2 
CD40LKO  no.  2  4.5  7.8 
CD40LKO  no.  3  8.8 
* Numbers represent total cell number recovered from indicated lymph node sources (axillary, brachial, etc.) per individual mouse. Data from three 
separate cohorts  of mice are presented. 
* x, mean total cell number per group. 
CD40LKO mice failed to mount an anti-TNP secondary re- 
sponse  of all  isotypes  except  IgM.  In  the  latter  case,  the 
CD40LKO  mice developed a low  IgM anti-TNP response 
in  the first  of two  independent  experiments  (Fig.  4).  In a 
second experiment,  one of three CD40LKO mice exhibited 
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an IgM Ag-specific response  that  was comparable to that 
of one of the control mice.  These results demonstrate  that 
CD40L-deficient  mice are incapable of undergoing  Ig class 
switching but  can secrete a variable amount  of IgM in re- 
sponse  to  a  TD  Ag. 
Certain antigens such as bacterial polysaccharides are capable 
of eliciting humoral immune responses in the apparent ab- 
sence of T  cell help (34-36).  The ability of CD40LKO mice 
to produce specific antibody in response to a T  independent 
Ag was assessed as follows. Mice were immunized with DNP- 
Ficoll,  a TI-2 Ag,  and bled 10 d  later for determination  of 
anti-TNP antibody levels. Serum from both CD40LKO and 
control mice exhibited strong IgM and IgG3 anti-TNP titers 
after DNP-Ficoll immunization  (Fig.  5). Both sets of mice 
also produced detectable titers of IgA, IgG1, and IgG2b anti- 
TNP, a result which was reproduced in a second experiment 
(data not shown). There were notable differences in the titra- 
tion curves between control and CD40LKO sera. For example, 
in the case of IgG2b anti-TNP the serum samples from the 
Figure  3.  Total  Ig isotypes  in nonimmune serum. Control (o/x,n  symbols) 
and CD40LKO mice (solid symbols) were bled successively  at 30, 44, 58, 
and 72 d of age. An isotype-specific  sandwich ELISA technique was used 
to assay  serum samples  (1:10 to 1:600,000 dilutions) as described  in Materials 
and Methods. Values are means (_+ SEM) from each group and are presented 
as/xg/ml (ng/ml for ]gE). 
1894  Humoral Immune Responses in CD40 Ligand-deficient Mice Table  3.  CD4OLKO Mice Fail To Generate Secondary TD Ag-specific Antibody  Responses 
Serum anti-TNP titers (U/ml)* 
Isotype  CD40LKO  (n  =  3)  Control no.  1  Control no.  2 
IgA  <10  9,485  457 
lgE  <10  6,978  2,003 
IgG1  <10  626,000  140,000 
IgG2a  <10  64,275  2,661 
IgG2b  <10  149,000  34,066 
IgG3  <10  316  5,858 
* Control and CD40LKO  mice were primed and challenged with TNP-KLH. Serum anti-TNP isotype levels were determined by ELISA and data 
were analyzed as described in Materials and Methods. Results are presented as U/ml based upon the dilution giving a half-maximal OD value relative 
to an arbitrarily selected maximum value. 
four CD40LKO mice exhibited considerably higher maximum 
OD values relative to controls (Fig. 5). In contrast, control 
and CD40LKO sera had essentially identical endpoint titers. 
This difference is likely due to the nature of the "capture" 
ELISA assay, in which total Ig isotype is captured before the 
addition of Ag (TNP-BGG). In the experiment summarized 
in Fig. 5, total serum IgG2b levels were considerably higher 
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Figure 4.  CD40LKO mice generate weak secondary lgM anti-TNP- 
KLH antibody responses. Mice (two control and three CD40LKO each 
in two independent experiments) were immunized with TNP-KLH and 
assayed for IgM anti-TNP responses as described in Table 3. Results are 
presented as OD units from ELISA assays. 
animals (mean  =  8/~g/ml).  Therefore,  if anti-TNP levels 
were equivalent in both CD40LKO  and control sera, then 
the percent of total IgG2b that was TNP-specific would be 
'~25-fold lower in the control mice than in CD40LKO mice. 
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Figure 5.  CD40LKO mice secrete multiple isotypes of Ag-specific  an- 
tibody in response to a TI-2 Ag. Control and CD40LKO mice were in- 
jected intraperitoneally with 10 #g DNP-FicolI. Mice were bled 10 d later 
and serum anti-TNP isotype responses were determined by ELISA as de- 
scribed in Table 3. Each line represents an ELISA titration curve from an 
individual animal. 
1895  Renshaw  et al. Table  4.  CD4OLKO B  Cell Proliferative Responses* 
Stimulus 
[3H]TdR incorporation 
+ IL-4/IL-5  CD40LKO  Control 
qgm 
None  -  76 (22)  72 (15) 
+  1,494  (131)  2,659  (62) 
LPS  -  20,508  (608)  25,024  (629) 
(1 #g/ml)  +  26,598  (1,110)  28,430  (2,922) 
Anti-IgM  -  799 (59)  1,775 (93) 
(10 #g/ml)  +  7,356  (969)  10,790 (1,893) 
CD40L  -  2,284  (162)  3,337  (44) 
(3 #g/ml)  +  19,674 (1,454)  21,112  (1,778) 
* Splenic B cells from CD40LKO and control mice were cultured for 
3 d with various stimuli and proliferation was measured as incorporation 
of tritiated thymidine as described in Materials and Methods. Data are 
presented as mean cpm (_+ SEM) for triplicate samples. 
Thus,  at higher  serum concentrations  where saturation  of 
the anti-IgG2b capture step is occurring, the detectable levels 
of anti-TNP IgG2b would be underestimated in the control 
mice. This interpretation notwithstanding,  the results dem- 
onstrate that CD40LKO mice are capable of mounting a hu- 
moral immune response to a TI Ag and can switch to iso- 
types other  than  IgM. 
CD4OLKO-den'ved B CeII Responses In Vitra  Splenic B cells 
were purified from CD40LKO mice in order to assess their 
ability to respond to stimulators of B cell growth and differen- 
tiation in vitro. As shown in Table 4, B cells from CD40LKO 
and control mice exhibited comparable proliferative responses 
to LPS,  anti-IgM,  and recombinant  soluble CD40L in the 
presence and absence of cytokines (IL-4 plus IL-5).  B cells 
from CD40LKO and control mice were also tested for their 
ability to  secrete Ig in  response to  cytokines plus  LPS or 
CD40L. CD40LKO-derived B cells are capable of responding 
to either stimulus, although the relative levels of IgM, IgE, 
and IgG1 were somewhat lower than was seen in control B 
cells (Table 5). The results indicate that the CD40LKO mice 
retained a capacity for Ig class switching despite the absence 
of CD40L expression in vivo. 
Histological Findings  in the LNs and Spleens of Immunized 
CD4OLKO Mice.  Inguinal LNs and spleens were obtained 
from CD40LKO mice and littermate controls that had been 
immunized and challenged with the Ag TNP-KLH. Hema- 
toxylin and eosin staining revealed  the presence of primary 
follicles in the LNs of both immunized CD40LKO mice and 
control mice. Prominent germinal center (secondary follicle) 
formation, however, was only observed in the LN and spleen 
of littermate  control mice (Fig.  6, A  and B). No germinal 
center formation could be observed in either the LN or the 
spleen of immunized CD40LKO mice (Fig. 6, C-E). Other 
histological findings in the LN and spleen in the CD40LKO 
mice  were unremarkable  when  compared  with  littermate 
controls. 
Discussion 
CD40L is an inducible type II membrane glycoprotein found 
on the surface of T cells after antigenic stimulation. Although 
CD40L has diverse activities including  the induction  of B 
and T  cell proliferation,  cytokine production from T  cells, 
monocytes, and plasma cells,  and macrophage  tumoricidal 
activity (15, 19-22, 37), these effects are also induced by sev- 
eral other cytokines. CD40L has a unique role in the initia- 
tion of B cell affinity maturation and isotype switching that 
occurs in the germinal centers of secondary lymphoid tissue 
after antigenic challenge. Evidence for the essential require- 
ment of CD40L in this process came from studies of HIGM 
patients who lack functional CD40L (38). These individuals 
are unable to produce high affinity Ag-specific Ig of isotypes 
other than  IgM and lack germinal  centers. 
In this report, we describe the generation of CD40LKO 
mice in which the CD40L gene has been disrupted, resulting 
in a failure to express a functional  CD40L protein  on the 
Table  5.  CD4OLKO B  Cell Immunoglobulin Secretion In  Vitro* 
IgM  IgG1  IgE 
Costimulus  CD40LKO  Control  CD40LKO  Control  CD40LKO  Control 
None  2  1  ND  ND  ND  ND 
LPS  28,145  46,416  361  651  288  509 
(585)  (6)  (15)  (73)  (27)  (132) 
CD40L  12,906  24,140  1,562  1,702  3,913  6,816 
(1,104)  (1,671)  (329)  (103)  (265)  (1,332) 
* Splenic B cells from CD40LKO and control mice were cultured for 6 d with either purified recombinant CD40L (3 #g/ml), LPS (10 ~g/ml), 
or no costimulus. All cultures contained IL-4 and IL-5, (10 ng/ml each). Culture supernatants were assayed  for Ig isotype  levels by ELISA as described 
in Materials and Methods. Data are presented as mean ng/ml  (_+ SEM) for triplicate samples. ND, below detectable limits. 
1896  Humoral  Immune Responses in CD40 Ligand-deficient Mice Figure 6.  Germinal center formation is not observed in CD40LKO mice after Ag challenge. Mice were immunized with TNP-KLH as described 
in Fig. 4. LNs and spleen were stained with hematoxylin and eosin and analyzed histologically for the presence of germinal centers. The following 
abbreviations are used: GC, secondary follicle with germinal center; LZ, light zone; DZ, dark zone; A, arteriole surrounded by lymphatic  sheath; 
WP, white pulp; PF, primary follicle, PALS, periarteriolar  lymphocyte sheath.  The original magnification is either 20x  or 40x. 
1897  Renshaw  et al. cell surface.  When immunized  with  a TD Ag,  these mice 
resemble their human counterparts with HIGM syndrome; 
they are unable to form germinal centers and produce only 
Ag-specific IgM. Despite such defects in isotype switching, 
B cell development appears unaffected in these mice, which 
have relatively normal percentages of B cells in the circula- 
tion and lymphoid tissues. Furthermore, B cells isolated from 
CD40LKO mice are able to proliferate and secrete a profile 
of Ig isotypes comparable to control mice when cultured with 
recombinant CD40L or LPS and cytokines, indicating that 
the defect in Ig production  seen in these mice is restricted 
to the TD help provided during B cell differentiation.  De- 
spite CD40L having stimulatory activity on T cells (20, 22), 
these populations in the CD40LKO mice appear normal with 
respect to proliferative responses to concanavalin  A and phyto- 
hemagglutinin  (data not  shown). 
Serum levels of different Ig isotypes in the unimmunized 
CD40LKO mice were compared with those of normal con- 
trol animals.  As CD40LKO mice matured,  their sera con- 
tained significantly lower amounts of IgG1, IgG2b, and IgA 
relative to controls, and no detectable IgE. IgG3 levels were 
somewhat reduced at 72 d of age, but the levels of IgM present 
were essentially normal. This profile of murine serum Ig iso- 
types is qualitatively similar to that reported for HIGM pa- 
tients, although the effect in the latter is quantitatively more 
dramatic. It will be important to determine whether the mu- 
fine serum isotype differences become more pronounced, and 
thus more reflective of the HIGM serum profile, with fur- 
ther aging.  It is noteworthy that an age-dependent decrease 
in serum IgG1 was observed in CD40LKO mice. This pre- 
sumably reflects the presence of maternal  IgG1  still in the 
circulation  of young mice (39-41). 
The defects in response to TD Ag in CD40LKO mice con- 
trast  with  their response to TI Ag.  TI-2  antigens  such as 
bacterial polysaccharides are able to induce a strong humoral 
response in vivo in the absence of T  cells (34-36).  Immuni- 
zation of mice with TI-2 antigens results in significant levels 
of Ag-specific IgM and IgG3 in the serum (34, 42, 43).  It 
is clear,  however,  the Ag alone is insufficient  to induce Ig 
secretion; soluble cytokines are required which regulate the 
profile of isotypes produced. When immunized with DNP- 
Ficoll,  both  CD40LKO  and  control  littermates  produced 
strong IgM and IgG3 anti-TNP  titers,  typical of responses 
to this antigen.  It is interesting to note that both sets of im- 
munized mice produced detectable amounts of IgG1, IgG2b, 
and IgA anti-TNP antibody but no TNP-specific IgE. The 
ability of the CD40LKO mice to generate anti-TNP  Ig of 
isotypes other than IgM confirms Ig isotype switching can 
be induced in response to Ag in the absence of CD40L. These 
findings concur with those of previous studies with normal 
mice where anti-IgD conjugated to high molecular weight 
dextran has been used to mimic the repeating epitopes common 
in bacterial polysaccharide antigens (42, 43). In the presence 
of IL-5, anti-IgD-dextran can stimulate resting B cells to se- 
crete high  levels of IgM and IgG1,  or IgG3 and IgG2a in 
the presence of IFN-3' in a T cell-independent manner (44, 
45). In contrast to B cells stimulated with LPS, the combina- 
tion of anti-IgD-dextran and IL-5 does not induce IgE secre- 
tion in  the presence of IL-4  (45,  46). 
It  has  recently been demonstrated  that  B-1  (CD5 +)  B 
cells, when activated with LPS, can undergo isotype switching 
in the presence of IL-4 and IL-5 (47). Although the origin 
of B-1 B cells remains controversial,  it has been suggested 
that cells of this phenotype may arise following interaction 
with TI-2 Ag in the absence of any contact with helper T 
cells (48, 49).  It is possible therefore,  that  the humoral re- 
sponse to TI-2 Ag observed in both CD40LKO and control 
mice  is  mediated  by  B-1  B  cells.  However,  in  neither 
CD40LKO nor control mice immunized with TNP-Ficoll 
was an increase in the proportion of B cells expressing CD5 
observed, compared with that of untreated animals (data not 
shown).  It remains to be determined whether Ig secretion 
is elevated from B-1 B cells following immunization  with 
TI-2  Ag. 
In summary, mice lacking CD40L are unable to undergo 
Ig isotype switching in response to a T-dependent Ag and 
fail to develop germinal centers upon antigenic stimulation. 
In contrast,  the response to T-independent  Ag appears  to 
be unimpaired,  with the production of Ag-specific IgG evi- 
dence  that  isotype switching  can  occur in  the  absence of 
CD40L. CD40LKO mice constitute a model which will be 
of value in determining the roles that CD40L, related mole- 
cules and soluble cytokines play at critical stages of the im- 
mune response, and will help to define the function of mole- 
cules that  share certain biological activities of CD40L. 
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